Neonates on heart-lung bypass get NO to prevent kidney injury
Part of Genetic & congenital, Heart & circulation clinical trials.
This Phase 3 study tests whether not giving nitric oxide during heart-lung bypass in newborns helps reduce the risk of acute kidney injury. It focuses on newborns having heart surgery for congenital heart disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a newborn baby who is 31 days old or younger
- Your baby is scheduled for heart surgery using a heart-lung machine for a congenital heart problem
- No parent/guardian consent issues—you must be able to give permission
- The surgery must not be an emergency
- Your baby is not extremely premature and has enough weight (at least 36 weeks and 2 kg)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special way of running the heart-lung bypass machine during planned heart surgery can help protect your kidneys and reduce the risk of kidney injury after the operation.
This trial studies whether giving nitric oxide during heart-lung bypass surgery can help protect a baby’s brain and kidneys. If you qualify, the study team will check outcomes after surgery to see if benefits happen compared with usual care.
This study tests whether inhaled nitric oxide—a gas that helps relax blood vessels—can prevent kidney injury in patients at high risk during heart surgery. If it works, it could reduce serious kidney complications after surgery.
This trial tests whether giving nitric oxide gas during heart surgery can help patients recover faster and need less breathing and circulation support afterward. It is for people having planned heart or aortic surgery with a heart-lung machine for the first time.
This trial tests whether inhaled nitric oxide gas can help full-term newborns who have severe breathing problems and high blood pressure in their lungs. It aims to improve oxygen levels and reduce the need for more intensive support.
This study tests whether a medication called nesiritide (a heart-supportive drug) can prevent kidney damage that sometimes occurs after heart surgery with a heart-lung machine. Patients at higher risk for this kidney injury are being enrolled to see if the medication helps protect their kidneys.
Hear when a new AKI trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.